Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER vs ISMOTIC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mannitol is an osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into the extracellular fluid and bloodstream, thereby reducing cerebral edema and promoting diuresis. Dextrose provides a source of calories and may help prevent hypoglycemia.
Isosmotic solution of mannitol; increases plasma osmolality, drawing water from tissues into the vasculature and reducing intracranial/intraocular pressure via osmotic diuresis.
Reduction of intracranial pressure,Reduction of intraocular pressure,Promotion of diuresis in oliguric acute renal failure (prophylaxis or treatment),Osmotic diuresis for drug overdose (e.g., salicylates, barbiturates),Irrigation solution during transurethral prostatic resection
Reduction of elevated intracranial pressure,Reduction of elevated intraocular pressure,Promotion of diuresis in acute renal failure (off-label)
Adult: 50-100 g (500-1000 m L of 10% solution) intravenously over 1-2 hours, repeated as needed every 6-12 hours. Individualize based on urine output and serum osmolality.
1-2 g orally every 6-8 hours, maximum 8 g/day; or 1-2 g intravenously over 5-10 minutes every 6-8 hours, maximum 8 g/day.
Terminal elimination half-life of mannitol is approximately 1.5-2 hours in patients with normal renal function. Clinically, duration of osmotic diuresis parallels half-life; in renal impairment, half-life may extend to 24-36 hours, increasing risk of fluid overload and electrolyte disturbances.
4.5-6.0 hours in adults with normal renal function; prolonged in renal impairment (up to 24-48 hours in anuria)
Mannitol is not significantly metabolized; it is excreted unchanged by the kidneys. Dextrose is metabolized via glycolysis to pyruvate and lactic acid, and enters the Krebs cycle for energy production.
Not significantly metabolized; primarily excreted unchanged by the kidneys.
Primarily renal excretion: Mannitol is filtered by glomeruli and not reabsorbed, excreted unchanged in urine (approximately 80-90% within 24 hours). Biliary/fecal elimination is negligible (<5%). Dextrose is metabolized to CO2 and water; any excess is excreted renally as glucose if threshold exceeded.
Renal: 90-95% unchanged; biliary/fecal: <5%
Mannitol is not significantly bound to plasma proteins (<1%). Dextrose is not protein bound.
<10% (negligible), primarily albumin
Approximately 0.5-0.6 L/kg. Mannitol distributes primarily in extracellular fluid (ECF); it does not enter cells significantly. Clinically, this low Vd indicates confinement to ECF, important for osmotic effects.
0.5-0.7 L/kg; limited to extracellular fluid compartment
Intravenous: 100% bioavailability. Oral bioavailability is negligible (<10%) as mannitol is poorly absorbed and acts as an osmotic laxative; Dextrose is well absorbed orally (100%) but not relevant for this IV formulation.
Oral: 60-70% (first-pass metabolism); Intravenous: 100%
Contraindicated in anuria or severe renal impairment (GFR < 20 m L/min). For GFR 20-50 m L/min, use with caution and monitor serum osmolality; reduce dose or extend interval. No specific dose reduction formula established.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: administer every 12 hours; GFR <10 m L/min: administer every 24 hours.
No specific adjustments required for hepatic impairment. Monitor fluid and electrolyte balance due to potential volume expansion.
No adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Avoid in severe hepatic impairment (Child-Pugh C) due to risk of hepatic encephalopathy.
0.25-1 g/kg (2.5-10 m L/kg of 10% solution) intravenously over 30-60 minutes, repeated as needed. Max dose 2 g/kg/day. Adjust based on response and serum osmolality.
25-50 mg/kg orally every 6-8 hours, maximum 2 g/dose; or 25-50 mg/kg intravenously over 5-10 minutes every 6-8 hours, maximum 2 g/dose.
Use lower initial doses and monitor renal function and electrolytes closely due to age-related decline in renal function and higher risk of volume overload. Start at 25-50 g (250-500 m L of 10% solution) and titrate.
Initiate at low end of dosing range (1 g every 8 hours) due to age-related renal function decline; adjust based on creatinine clearance.
None.
None.
Monitor serum electrolytes, osmolality, and renal function during therapy,May cause fluid and electrolyte imbalances, including hyponatremia or hypernatremia,Administer cautiously in patients with renal impairment, heart failure, or pulmonary edema,Use with caution in conditions where increased intravascular volume may be harmful,Do not administer if solution contains particulate matter or is discolored
Monitor renal function and serum electrolytes,Avoid in patients with anuria or severe renal impairment,Risk of pulmonary edema, heart failure, and electrolyte disturbances
Anuria due to severe renal disease,Severe dehydration,Intracranial hemorrhage (unless during craniotomy),Active intracranial bleeding except during craniotomy,Hypersensitivity to mannitol or dextrose,Congestive heart failure,Pulmonary edema
Anuria,Severe renal failure,Congestive heart failure,Active intracranial bleeding (except during craniotomy),Hypovolemia
No clinically relevant food interactions.
Avoid high-tyramine foods (aged cheeses, cured meats, soy products) as hydralazine may increase tyramine sensitivity? No significant specific food interactions for isosorbide dinitrate/hydralazine. However, limit high-salt foods to manage heart failure. Avoid alcohol due to additive hypotensive effects.
No evidence of teratogenicity in animal studies; limited human data. Mannitol crosses the placenta; risk of fetal electrolyte disturbances and dehydration with maternal overdose. First trimester: theoretical risk only, no reported malformations. Second/third trimesters: monitor for maternal hyperosmolality and fluid shifts which may affect fetal hydration status.
No adequate and well-controlled studies in pregnant women. In animal studies, administration of isosorbide dinitrate (active ingredient of Ismotic) during organogenesis produced fetal toxicity at doses 35 times the maximum human dose. First trimester: unknown risk, avoid unless clearly needed. Second and third trimesters: risk of maternal hypotension and reduced placental perfusion; use only if potential benefit justifies risk. Should be used with caution near term due to risk of neonatal hypotension.
Not known if mannitol or dextrose are excreted in breast milk. Consider risk of osmotic diarrhea in neonate if present in milk. M/P ratio not established.
Isosorbide dinitrate is excreted in human breast milk; clinical significance unknown. M/P ratio not reported. Caution is advised; consider temporary discontinuation of breastfeeding during therapy.
No specific dose adjustment recommended; monitor maternal fluid status closely as pregnancy increases risk of pulmonary edema; adjust rate based on urine output and osmolality.
Pregnancy may alter pharmacokinetics: increased plasma volume and renal clearance may reduce drug concentrations. However, no specific dose adjustments are recommended; titrate based on clinical response and tolerability. Start at lowest effective dose, increase cautiously. Avoid rapid dose escalation. Consider lower doses in third trimester due to increased sensitivity to vasodilation.
Monitor serum sodium and osmolality closely; risk of hypernatremia and acute kidney injury. Use an in-line filter to prevent crystallization. Administer by slow IV infusion to avoid fluid overload. Contraindicated in anuria and severe pulmonary edema.
ISOMOTIC (isosorbide dinitrate/hydralazine) is a fixed-dose combination for heart failure in self-identified Black patients. Monitor for hypotension, headache, and dizziness. Avoid use with PDE-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension. Titrate gradually to target dose to minimize adverse effects. May cause drug-induced lupus-like syndrome or peripheral neuropathy with hydralazine; consider slow acetylator phenotype risk.
Report any signs of fluid overload like shortness of breath or swelling.,This medicine may cause increased urination and thirst.,Do not take this medication by mouth; it is for intravenous use only.,Inform your healthcare provider if you have kidney problems or heart failure.
Take this medication exactly as prescribed to control your heart failure symptoms.,Do not take erectile dysfunction medicines (like sildenafil, tadalafil) while on this drug, as it can cause a dangerous drop in blood pressure.,You may experience headaches, dizziness, or lightheadedness when starting; these often improve over time. If severe, contact your doctor.,Avoid alcohol, which can worsen dizziness and low blood pressure.,Report any unexplained joint pain, fever, rash, or numbness/tingling in your hands or feet to your doctor immediately.,Swallow tablets whole; do not crush or chew.,Do not stop suddenly without consulting your doctor; abrupt discontinuation can worsen heart failure.
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER vs ISMOTIC, answered by our medical review team.
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER is a Osmotic Diuretic that works by Mannitol is an osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into the extracellular fluid and bloodstream, thereby reducing cerebral edema and promoting diuresis. Dextrose provides a source of calories and may help prevent hypoglycemia.. ISMOTIC is a Osmotic Diuretic that works by Isosmotic solution of mannitol; increases plasma osmolality, drawing water from tissues into the vasculature and reducing intracranial/intraocular pressure via osmotic diuresis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER and ISMOTIC depend on the specific clinical indication. These are both Osmotic Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER is: Adult: 50-100 g (500-1000 m L of 10% solution) intravenously over 1-2 hours, repeated as needed every 6-12 hours. Individualize based on urine output and serum osmolality.. The standard adult dose of ISMOTIC is: 1-2 g orally every 6-8 hours, maximum 8 g/day; or 1-2 g intravenously over 5-10 minutes every 6-8 hours, maximum 8 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER and ISMOTIC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER is classified as Category A/B. No evidence of teratogenicity in animal studies; limited human data. Mannitol crosses the placenta; risk of fetal electrolyte disturbances and dehydration with maternal overdose. F. ISMOTIC is classified as Category C. No adequate and well-controlled studies in pregnant women. In animal studies, administration of isosorbide dinitrate (active ingredient of Ismotic) during organogenesis produced fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.